Sign In
NewsRadar

Search Press
Looking for press releases of a particular company? Enter company name (or keyword) here.

   


Apposite Capital promotes Dr Chris Hollowood to partner


London, UK – 7th December 2010. Apposite Capital, the healthcare specialist investment firm, today announces the promotion of Dr Chris Hollowood to Partner.

Chris has been part of Apposite Capital’s investment team since 2007, where he helps oversee investments in Life Sciences, as well as being closely involved in the firm’s direct secondary activities. Chris is currently a member of the board of directors of Anaphore Inc, Convergence Pharmaceuticals Ltd and Zonare Medical Systems Inc.

Chris started his investment career as a fund manager with Neptune Management, with responsibility for Healthcare sector investments, before moving into Healthcare focused venture capital and corporate advisory at Bioscience Managers. He attained his first degree in Natural Sciences, specialising in Chemistry, and a PhD in Organic Chemistry, both from Cambridge University.

Commenting on today’s announcement, David Porter, Managing Partner of Apposite Capital, said: “We are delighted to welcome Chris to the Partnership. Chris has made considerable contributions to date managing a number of our Life Sciences primary investments. He has also been instrumental in setting up and strengthening our direct secondary activities, which is an area we wish to continue to expand moving forward.”

ENDS

Media contact:
Valerie Auffray
Tel: +44(0) 20 7090 6383
Email: valerie.auffray@appositecapital.com


About Apposite Capital
www.appositecapital.com

Apposite Capital is an independent investment firm focused exclusively on Healthcare. The firm invests in private companies involved in Healthcare Services and Life Sciences on a primary basis, as well as acquiring and managing direct Healthcare assets in the secondary market.

Apposite has an in-depth sector knowledge covering all aspects of the healthcare industry globally, with a unique unrivalled reach to Japan. The investment team combines complementary entrepreneurial, private equity and investment banking skills.

Apposite has built a high quality primary portfolio of companies in the US and Europe. The firm invests in seasoned management with a clear vision and is committed to adding value to its portfolio companies. Apposite balances its investments across all stages of company development, providing venture, development and growth financings as well as buyout capital. Apposite typically invests as a lead investor and has a representation at the Board of Directors.

Created in 2006, Apposite is headquartered in London, UK and has a presence in San Francisco, CA, USA.


Publisher Contact Information:

Apposite Capital
+44 (0) 20 7090 6383
valerie.auffray@appositecapital.com

Company profile of Apposite Capital
Past press releases of Apposite Capital.

Data


27,722
Tech investments
From our Online Data Service
17,881
VC-backed companies
From our Radar


Recent Deals


DATEAMOUNTSECTOR
Dec 21€50.0MKnowledge management
Dec 20€16.0MSemiconductors
Dec 17€18.0MOther Computers & Electronics
Dec 17€5.2MBiotechnology
Dec 17€17.0MBusiness applications
Dec 15€17.0ME-Commerce
Dec 4€3.3MNanotechnology

For information on Europe's most extensive database on technology funding click here!

Events



Press Releases


Sep 30
TetaVi
tetavi raises $6 million to help more companies bring 3d holograms ...

May 28
Identiq
identiq raises $5m seed, launches privacy-first identity validation...

Apr 29
Nethone
nethone raised over $1 million from innovation nest

Mar 31
CompPair
the fit allocates chf 100'000 to comppair technologies

Jan 29
Yumpingo
yumpingo raises $10m to transform guest experiences in restaurants





About usContact usLegal Information
Copyright © 1999-2019
Emerging Technology Research Europe Inc. All rights reserved.